NEW YORK, Nov. 10, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Dr. Reddy's Laboratories Ltd. ("Dr Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at email@example.com or 212-697-6484.
The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On November 6, 2015, the Company disclosed that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India.
Following this news, shares of Dr. Reddy's fell $11.75 per share or over 18% to close at $53.50 per share on November 6, 2015,
If you are aware of any facts relating to this investigation, or purchased shares of Dr. Reddy's you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC